Introduction
In 1897, Victor Eisenmenger described a young adult with cyanosis and dyspnoea due to a large ventricular septal defect (VSD) who died of massive haemoptysis. 1 Sixty-one years later, in his landmark papers, Paul Wood described the mode of death of 42 patients with Eisenmenger syndrome (ES). 2 Haemoptysis was the leading cause of death, accounting for 29% of the cases, but attempted surgical repair of the congenital heart defect and heart failure were also common causes. Omitting three deaths in infancy, mean patient age at death was 33 and 36 years among those with post-tricuspid and pretricuspid valve defects, respectively. Forty years later, in 1998, Daliento et al. 3 reported that little had changed in the overall prognosis of ES relative to Wood's observations, thus questioning whether improvements in clinical understanding had any appreciable effect on the care and outcome of this population. However, cause-specific mortality in the two reports differed substantially; in the subsequent report, heart failure was the single most frequent cause, accounting for 23% of all deaths, followed by haemorrhage (mainly haemoptysis), peri-operative, and sudden death. Several other have investigated cause-specific mortality in patients with ES; mainly single-centre studies with limited numbers of deaths and varying definitions and classifications of mortality. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] This present long-term study on a large, multicentre ES cohort aimed to describe cause-specific mortality, and examine whether the cause of death has changed during the study period in the context of recent advances in the management of ES.
Methods
This was a retrospective, descriptive multicentre study on patients with ES. Data were collected from medical records of all known ES patients under active follow-up at any time between 1977 and 2015 in 13 countries (Denmark, Norway, Sweden, Finland, United Kingdom, Belgium, Netherlands, Poland, Lithuania, Slovenia, Italy, China, and USA). Time and cause of death were verified from the medical records and/or national mortality databases. Patients who received heart-lung or lungtransplantation were excluded from further analysis 30 days after the transplantation.
Eisenmenger syndrome was defined as pulmonary arterial hypertension in the presence of a large non-restrictive intra-or extra-cardiac shunt, accompanied by cyanosis (peripheral oxygen saturation < 92% at rest or <87% during exercise, or clinically described cyanosis at rest). 2, [12] [13] [14] [15] Patients were classified according to congenital cardiac defect into simple pre-tricuspid (atrial septal defects), simple post-tricuspid (VSD, patent ductus arteriosus, and aorto-pulmonary window), and complex lesions (atrio-VSD, univentricular hearts, transposition of the great arteries, and truncus arteriosus). 12 Patients with more than one lesion were assigned to the lesion of highest complexity according to Allan et al.
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Cause-specific mortality was defined as the disease or condition directly leading to death, as per World Health Organization guidance. 17 Additional antecedent causes were not considered. In cases where the cause-specific mortality was uncertain, the case was reviewed with a coinvestigator and consensus was reached. Patients with insufficient data on cause-specific mortality were excluded from the analysis.
Given the advances in treatment and the changes in follow-up strategies for patients with ES, the study period was subdivided into two eras. 13, 14, 18, 19 The 'early' era spanned from study enrolment until 30 June 2006; the time of the publication of the BREATHE-5 trial 20 on safety and efficacy of the endothelin receptor antagonist bosentan, leading to formal introduction of advanced therapy (AT) to patients with ES and has, arguably been one of the most important advances in the management of these patients. The 'late' era spanned from 1 July 2006 until death or the end of follow-up in September 2015. Cause-specific mortality was compared between the two eras and also to historic cohorts. The study complies with the Declaration of Helsinki and was approved by the ethics committees in all participating countries. As this was a retrospective study based on existing patient data, the requirement for individual informed consent was waived. Data were anonymized prior to sharing across borders. 
Statistical analysis

Cause-specific mortality
Cause of death could be identified in 74% of patients (n = 411). The proportion of cases with an unknown cause of death was equally distributed between patients with and without Down syndrome (24.4 vs. 27.8%; P = 0.384) and between shunt subgroups (25.6 vs. 28.0 vs. 25.3%; 1 vs. 2: P = 0.656; 1 vs. 3: P = 0.961; and 2 vs. 3: P = 0.497, respectively). The proportion of unknown causes of death varied among the participating countries (median 31.6%; IQR 5.6-43.0%). Among patients with known causes of death, the leading cause was heart failure (34.3%), followed by infection (26.3%) and sudden cardiac death (SCD, 10.0%; Table 2 ). Infections were dominated by pneumonia (60.7%), sepsis (20.6%), and cerebral abscesses (8.4%), whereas only two patients died from endocarditis (1.9%). Nearly half the patients (43.9%) succumbing to SCD had an arrhythmia verified by electrocardiography within hours prior to death. Death due to thromboembolism and haemorrhage ranked 4th and 5th, respectively. Thromboembolism was dominated by stroke (38.2%) and pulmonary embolism (29.4%). Haemoptysis accounted for only 3% of mortality and there were two autopsy-verified fatal cases of rupture of the main pulmonary artery. Twenty-seven patients (6.6%) died peri-procedurally; 51.9% in relation to non-cardiac surgery, the remaining in relation to cardiac surgery (18.5%), transplantation (18.5%), or catheter-based cardiac interventions (11.1%). There were no data regarding the total number of surgeries in the cohort; hence, we could not to estimate surgical mortality. Other causes of death, including cancer (2.3%), trauma (0.7%), and pregnancy (0.2%) were uncommon.
There was no overall difference in cause-specific mortality between age groups (<20, 20-40, 40-60, and >60 years) (P = 0.115) or between the three different shunt subgroups (P = 0.253; Figure 1 ). Heart failure and infection were the leading causes of death in all age groups and shunt types. There was a trend that heart failure was more prevalent in patients with simple post-tricuspid shunts than in patients with pretricuspid shunts (P = 0.076). There was a significantly higher proportion of deaths due to infection in patients with a simple pre-tricuspid shunt as compared to post-tricuspid shunt (P = 0.023). Peri-procedural deaths were more frequent in younger (age < 20 years) as compared to older patients (15 vs. 5%, P = 0.011; Figure 1 ), whereas thromboembolic mortality was highest in the older patients. Mortality from other causes increased with age and decreased with increasing lesion complexity; thus, patients with pre-tricuspid shunts died more frequently from other causes compared to patients with complex lesions (P = 0.028). The proportion of deaths due to infections was higher in ES patients with Down syndrome (36.8 vs. 19.6%; P < 0.001), whereas none of the remaining causes differed significantly in these patients.
Temporal changes in cause-specific mortality
Of the overall 558 deaths in this study, 261 (47%) occurred in the 'late' era. The cases with unknown cause of death were equally distributed between the 'early' and 'late' era ( The distribution of cause-specific mortality differed between the 'early' and 'late' era ( Table 2) . The proportion of patients dying from heart failure increased (P = 0.032), whereas the proportion who succumbed from thromboembolism (P = 0.014) and cardiac (P = 0.014) and non-cardiac (P = 0.004) peri-procedural deaths decreased. Most of the peri-procedural deaths (89%) occurred in the 'early' era. Cause-specific mortality in both 'early' and 'late' era from our study differed from previous reports (Figure 2) . As nearly half of the patients from the late era were survivors of the early era (see Supplementary material online S1), a comparison of the two groups: survivors of the early era and newly included patients in the late era, was performed. However, no difference in cause-specific mortality was noted (see Supplementary material online S4).
The role of at on cause-specific mortality in the late era
Of 1193 patients included in the late era, 261 died. Slightly more than half the deceased patients (137, 52.5%) received treatment with AT, whereas the remainder were AT-naïve. There was a trend that patients from the late era who received AT died at an older age than the AT-naïve patients (47.0 ± 15.9 vs. 43.2 ± 16.2 years; P = 0.058); however, this difference vanished when corrected for Down syndrome (49.1 ± 18.0 vs. 49.4 ± 16.6, P = 0.908; see Supplementary material online S5). Cause-specific mortality differed between the patients who received AT and those who did not (see Supplementary material online S5). The proportion of patients dying from infections was higher in the AT-naïve group (39.5 vs. 18.1%; P = 0.001), just as the proportion who succumbed from thromboembolism was higher in this group (8.1 vs. 1.9%; P = 0.043). There was a trend that death due to other causes was more frequent in AT patients (P = 0.082). There was no significant difference regarding heart failure (P = 0.121), SCD (P = 0.153), haemorrhage (P = 0.552), or peri-operative deaths (P = 0.682). The results were consistent after adjusting for Down syndrome.
Survival
Median survival in the cohort was 37.9 years, with no significant variation among participating countries. Median survival in the 'early' era was significantly shorter as compared to the 'late' era (35.2 vs. 52.3 years, P < 0.001; Table 1 ); however, the mean age of the patients did not differ (39.8 vs. 39.2 years, P = 0.376; Table 1 ). Patients with Down syndrome had a decreased longevity as compared to non-Down patients (34.8 vs. 39.0 years, P < 0.001) and patients with simple shunts had a decreased median survival (45.5 years) as compared to complex shunts (31.9 years; P < 0.001).
Discussion
This multicentre study, the largest study on ES to date, reports a change in cause-specific mortality over the last 40 years. Mortality in ES remains high, although improving. The main finding includes a shift in cause-specific mortality; in particular, mortality due to heart failure appears to be predominant in contrast to mortality due to haemorrhagic events and peri-procedural deaths. Overall, there were few deaths from haemoptysis and thromboembolism throughout the study compared to older reports, 2,3 whereas other causes of death, including cancer, have become more prevalent. Heart failure has previously been reported as a common cause of death in ES accounting for 7-23%. [2] [3] [4] [5] [6] 21 The usual clinical presentation of heart failure is often atypical in ES, and manifests as low cardiac output and increasing cyanosis, in contrast to pulmonary and peripheral oedema in traditional heart failure; nevertheless, these features may also be noted in ES. 22 The proportion of deaths attributable to heart failure has further increased in the 'late' era of our study, which may likely be associated with progressive right ventricular impairment. 22, 23 This may be explained in part by the increased longevity of ES patients in the current era of AT, although this is not extracted from our data and thus speculative. Limited tolerable treatment options for heart failure are available in ES patients. Prevention is also challenging; diuretics may be used cautiously, given patients preloaddependent state. In other cardiovascular settings, digoxin has been shown to increase mortality, 24 and a similar trend was found in ES.
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Other standard heart failure drugs, i.e. b-blockers, angiotensinconverting enzyme-inhibitors, and angiotensin receptor blockers may not share the problem of increasing mortality, although vasodilators should be carefully used due to the potential for systemic hypotensive effect. 25 However, in a single retrospective study of ES, patients treated with b-blockers were found to have better survival (hazard ratio 0.35; 95% confidence interval 0.13-1.00; P = 0.051). 11 There is currently no evidence that systematic use of AT actually delays the onset of heart failure, although AT has been shown to reduce BNP levels. 26 Interestingly, treatment with AT did not alter cause-specific mortality in terms of heart failure deaths; hence, it is likely that several other changes in follow-up and treatment strategy account for the observed changes from the early to late era. Beside the increase in heart failure-related deaths, the increased longevity of ES patients may partly explain the increase in cancerrelated and other deaths in the 'late' era ( Figure 2 ). This phenomenon was more prominent in patients with simple pre-tricuspid defects, the subgroup with the oldest patients. This has obvious clinical implications and underlines the importance of comorbidities in ES. Thus, it is vital that malignancies should be diagnosed at an early stage, and hence, major surgery or general anaesthesia can be avoided. Classical signs, such as anaemia, are difficult to apply in ES, and the abnormal haemostasis predisposing to bleeding could make early diagnosis of, e.g. gastro-intestinal malignancies challenging.
Opposed to earlier series 2,3 infections were a momentous cause of death in the present study, whether this is due to a true increase or rather due to methodology is speculative. In the present study, the proportion of infection-related deaths remained fairly constant from the 'early' to 'late' era. However, it was less frequent in patients treated with AT during the late era, compared to AT-naïve patients. To our knowledge, there is no evidence of decreased number of infections temporal with the introduction of AT in neither PAH associated with congenital heart disease or idiopathic PAH. Haemoptysis, previously shown to be a major cause of death among patients with ES, was a relative uncommon mortality cause in our series. Haemoptysis is nevertheless a frequent clinical event in ES; Daliento et al. 3 found that 20% of patients experienced at least one episode of haemoptysis, yet previous haemoptysis did not predict mortality in their series. Haemoptysis, nevertheless, was the cause of death in 11% from patients in their cohort. The overall proportion of deaths due to haemorrhage decreased throughout the study, and the current 6% is low compared to historic data. As patients with cyanotic congenital heart disease and secondary erythrocytosis are hypocoagulable, 27 may be considered in the ongoing debate on the routine use of anticoagulation in ES. 13, [27] [28] [29] However, the balance between haemorrhage and thromboembolism as causes of death tipped strongly towards the latter in patients older than 60 years.
. Thromboembolism-related mortality decreased significantly throughout the study. Whether this could be explained by increased awareness of the pitfalls of routine phlebotomy, including iron deficiency and thrombogenecity, 30, 31 better patient selection for anticoagulation, and monitoring of thrombo-prophylaxis, or other reasons, remains speculative. A similar decrease in thromboembolism-related mortality was observed in patients receiving AT. Since there is no evidence that AT may influence coagulability, this effect may be due to the complex nature of ES including the risk of phlebotomy and iron deficiency. Peri-procedural deaths, related to both cardiac and non-cardiac procedures, have declined since the historic 26% mortality reported by Wood.
2 Better identification of the individual risk profile, avoidance of non-essential surgical procedures, greater surgical and anaesthetic expertise, and better converging care to tertiary centres may have led to such changes. However, as the ES population ages, it is possible that the need for surgery may increase. The occurrence of malignancies, cholelithiasis, and dental extractions in patients with Down syndrome, are common indications for surgery. Although these procedures should be performed in tertiary centres, periprocedural morbidity and mortality remain significant. In this large cohort of patients with ES, we were able to reliably establish the cause of death in 74% of the patients; in the remainder, it is unlikely that peri-operative causes and major external haemorrhage have not been recorded. Sudden cardiac death due to arrhythmia or thromboembolism may be overrepresented among the unknown causes 3, 6, 7, 9 ; however, this remains speculative. This study has shown a trend of prolonged life-expectancy from the 'early' to the 'late' era. However, this observation may be biased as the incidence of new cases is decreasing; thus, the patients in the 'late' era mainly represent the survivors of the 'early' era. Mean age at death in both eras in our study was older than the 33 years reported by Wood 2 and that reported by Daliento et al. 3 for simple (32.5 ± 14.6 years) and complex (25.8 ± 7.9 years) lesions. The available data from the present study do not permit a deeper understanding of the reasons for the observed changes in cause-specific mortality. Previous studies have shown clear benefits of AT on haemodynamics, functional class, and exercise capacity, with evidence (albeit retrospective) of improved survival. 11, 20, 32, 33 Although the present study evaluated the effect of AT on cause-specific mortality, the observed alterations from the 'early' to the 'late' era suggest that several other factors besides the use of AT have influenced.
Although we have shown, herewith, a shift in cause-specific mortality, coincident with the current era of AT, evaluating survival and predictors of death was not the scope of this study. In addition to greater access to oral AT targeting pulmonary vascular disease, renewed management strategies-although not globally alignedhave also been implemented, and an increasing number of patients with ES are now being followed at tertiary centres with regular outpatient visits.
11 Abolition of routine phlebotomies with a move towards a converse approach and focus on identification and treatment of iron deficiency, are good examples of the recent changes in management of ES. 34 Similar avoidance of unnecessary risks, including pregnancy and surgery, and increased knowledge of peri-operative evaluation and management may have all contributed to the observed changes in age at death and cause-specific mortality.
Limitations of the study
This study has obvious limitations due to the nature of its design: retrospective data collection from several centres worldwide over a long time period with different strategies for treatment and followup. Because of variations in access to data of early era patients in different countries, only few countries contributed during the initial period, although all the countries contributed after 2000. This patient cohort was not representative of ES in the community or at secondary centres, as most patients (90%) were followed at a tertiary centre. Second, diagnostic misclassifications could not be excluded. All diagnoses were, however, verified by reviewing medical files before patients entered the study to ameliorate this. Confirmation of the diagnosis was not always possible because of incomplete data in the medical files. These cases were not included in the study. Therefore, exclusion of a minor number of false negative diagnoses may have occurred. As in all retrospective studies of cause-specific mortality, the validity of the cause of death was indeed dependent on the reporting physician. During the study period of 38 years, the classification and investigations of the cause of death may have changed and the use of autopsies has become much less frequent, which may have introduced a bias. Occasionally, there was limited access to data from patients who died early in the study period. This may have introduced important bias, even though for this to affect the results of our study would require different missing data by era in terms of the cause of death. Third, in five cases, the distinction between the primary cause of death and antecedent causes were not definitive. However, these unclear causes were discussed between investigators and adjudicated by consensus. The relative frequency of the ultimate cause of death may also not reflect the importance of disease burden contributing to death, since more distant causes were ignored; for instance, a patient with endocarditis may have been successfully treated with antibiotics but may experience complications of severe aortic regurgitation and subsequent heart failure months to years later. Moreover, there were a relatively high proportion of unknown causes of death, which may partly be explained by the fairly restricted interpretation of cause-specific mortality in this study. However, similar rates of unknown causes of death have been reported in previous studies. 2, 7 Finally, the division of eras was arbitrary and in the present study was set as the time at which AT was formally advocated for ES patients along several other gradual changes in care; however, no data on medication were assessed. Future prospective studies with longer period of observation may validate these findings and shed additional insight on the potential impact of improved core pathways on mortality and overall outcome in ES.
Conclusions
This study shows that despite changes in therapy, care, and follow-up of ES in tertiary care centres, all-cause mortality, including cardiac, remains high. Although our data do not establish a causal association, there seems to be a shift towards mortality at an older age, and from acute to chronic cardiac causes, primarily heart failure. Periprocedural death and death due to haemoptysis have become less common. Therefore, the prevention and optimal management of heart failure is becoming more important in patients with ES;
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